You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Indolent Non-Hodgkin's Lymphoma (iNHL) (excluding CLL)

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Patterns in People With Indolent Non-Hodgkin Lymphoma,Type of

Active, not recruiting
  • Relapsed or Refractory Indolent Non-Hodgkin Lymphoma
  • Copanlisib (BAY80-6946)
  • Multiple Locations, Taiwan
    Many Locations
Jan 31, 2023

Severe COVID-19 Infection in CLL or B-NHL Who Received

Not yet recruiting
  • Chronic Lymphocytic Leukemia
  • +2 more
    • (no location specified)
    Apr 6, 2023

    Obinutuzumab in Chinese Real-world Patients With iNHL

    Not yet recruiting
    • Lymphomas Non-Hodgkin's B-Cell
    • Changzhou, Jiangsu, China
    • +24 more
    Jul 23, 2023

    Lymphoma, Non-Hodgkin Trial in Beijing (Copanlisib (Aliqopa, BAY80-6946))

    Completed
    • Lymphoma, Non-Hodgkin
    • Copanlisib (Aliqopa, BAY80-6946)
    • Beijing, China
      Beijing Cancer Hospital
    May 17, 2021

    Indolent Non-Hodgkin Lymphomas/Chronic Lymphocytic Leukemia Trial in Bergamo (Blinatumomab Expanded T-cells (BET))

    Active, not recruiting
    • Indolent Non-Hodgkin Lymphomas/Chronic Lymphocytic Leukemia
    • Blinatumomab Expanded T-cells (BET)
    • Bergamo, Italy
      ASST - Papa Giovanni XXIII
    Dec 22, 2021

    Ann Arbor Stage I B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage I Grade 1 Follicular Lymphoma, Ann Arbor Stage I Grade 2

    Active, not recruiting
    • Ann Arbor Stage I B-Cell Non-Hodgkin Lymphoma
    • +22 more
    • External Beam Radiation Therapy
    • Orbital Radiation
    • Houston, Texas
      M D Anderson Cancer Center
    Dec 9, 2022

    CD20-positive Non-Hodgkin Lymphoma Trial in Seoul (Rituximab + MG4101)

    Terminated
    • CD20-positive Non-Hodgkin Lymphoma
    • Rituximab + MG4101
    • Seoul, Korea, Republic of
      Seoul National University Hospital
    Oct 24, 2022

    Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphomas Trial in Boston (Imprime PGG, Rituximab)

    Completed
    Has Results
    • Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphomas
    • Boston, Massachusetts
      Dana Farber Cancer Institute
    Sep 20, 2022

    Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Follicular Lymphoma, Recurrent Indolent Adult Non-Hodgkin Lymphoma Trial in

    Suspended
    • Recurrent B-Cell Non-Hodgkin Lymphoma
    • +7 more
    • Philadelphia, Pennsylvania
      Sidney Kimmel Cancer Center at Thomas Jefferson University
    Jan 20, 2023

    Non Hodgkin Lymphoma Trial in Australia, United States (Tenalisib,)

    Completed
    Has Results
    • Non Hodgkin Lymphoma
    • Huntsville, Alabama
    • +11 more
    Jul 20, 2021

    Non Hodgkin Lymphoma, Follicular Lymphoma, Indolent Lymphoma Trial in Miami, Baltimore, Milwaukee (Zydelig)

    Active, not recruiting
    • Non Hodgkin Lymphoma
    • +8 more
    • Miami, Florida
    • +2 more
    Apr 21, 2022

    Waldenstrom Macroglobulinemia Trial in United States (Umbralisib)

    Completed
    • Waldenstrom Macroglobulinemia
    • Washington, District of Columbia
    • +3 more
    Oct 19, 2022

    Grade 3a Follicular Lymphoma, Recurrent Follicular Lymphoma, Recurrent Grade 1 Follicular Lymphoma Trial in Houston (other,

    Completed
    • Grade 3a Follicular Lymphoma
    • +9 more
    • Laboratory Biomarker Analysis
    • +2 more
    • Houston, Texas
      M D Anderson Cancer Center
    Jan 31, 2023

    Inert Non Hodgkin's Lymphoma Trial in Beijing (IBI376, Rituximab)

    Recruiting
    • Inert Non Hodgkin's Lymphoma
    • Beijing, China
      Biotherapeutic Department, Chinese PLA General Hospital
    Feb 19, 2022

    B-cell Malignancy, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial (AS-1763)

    Not yet recruiting
    • B-cell Malignancy
    • +7 more
    • (no location specified)
    Oct 26, 2022

    Chronic Lymphocytic Leukemia, Indolent Non-Hodgkin Lymphoma, Follicular Lymphoma Trial in Aichi, Miyagi, Tokyo (Idelalisib)

    Completed
    Has Results
    • Chronic Lymphocytic Leukemia
    • +5 more
    • Aichi, Japan
    • +2 more
    Feb 24, 2021

    Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin Trial in France, Italy, Netherlands (Obinutuzumab, CC-122)

    Active, not recruiting
    • Lymphoma, Large B-Cell, Diffuse
    • Lymphoma, Non-Hodgkin
    • Borddeaux Cedex, France
    • +9 more
    Nov 11, 2022

    DLBCL - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma Trial (Bridging radiation therapy,

    Not yet recruiting
    • DLBCL - Diffuse Large B Cell Lymphoma
    • +6 more
    • Bridging radiation therapy
    • +2 more
    • (no location specified)
    Jan 4, 2023

    Recurrent Follicular Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Nodal Marginal Zone Lymphoma Trial (Acalabrutinib,

    Withdrawn
    • Recurrent Follicular Lymphoma
    • +8 more
    • (no location specified)
    Jun 2, 2022

    Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma Trial in Japan (ME-401)

    Active, not recruiting
    • Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma
    • Nagoya, Aichi, Japan
    • +5 more
    Dec 10, 2021

    Non Hodgkin's Lymphoma Trial in Sacramento, Santa Rosa (Rituximab, Lenalidomide)

    Active, not recruiting
    • Non Hodgkin's Lymphoma
    • Sacramento, California
    • +1 more
    Nov 15, 2021

    B-cell Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia Trial in Charleston (Cyclophosphamide injection, Fludarabine

    Not yet recruiting
    • B-cell Non Hodgkin Lymphoma
    • Chronic Lymphocytic Leukemia
    • Cyclophosphamide injection
    • +2 more
    • Charleston, South Carolina
      Hollings Cancer Center at Medical University of South Carolina
    Jan 18, 2023

    Follicular Lymphoma, Marginal Zone Lymphoma, Indolent Non-hodgkin Lymphoma Trial in Boston (Obinutuzumab, Glofitamab)

    Not yet recruiting
    • Follicular Lymphoma
    • +2 more
    • Boston, Massachusetts
      Dana-Farber Cancer Institute
    Mar 13, 2023

    Non-Hodgkin's Lymphoma, Relapsed, Chronic Lymphoid Leukemia in Relapse, Non-Hodgkin's Lymphoma Refractory Trial in United States

    Completed
    Has Results
    • Non-Hodgkin's Lymphoma, Relapsed
    • +8 more
    • PBCAR20A
    • +2 more
    • Duarte, California
    • +4 more
    Jan 4, 2023

    Lymphoid Leukemia, Small Lymphocytic Lymphoma, Lymphoma, Non-Hodgkin Trial in Madison (Bendamustine, Rituximab, Lenalidomide)

    Completed
    • Lymphoid Leukemia
    • +2 more
    • Madison, Wisconsin
      University of Wisconsin
    Jan 30, 2023